Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance.

Intervenir o diferir aneurismas de aorta abdominal en pandemia

Annual risk of rupture can be estimated based on a prospective cohort published by McGuinness et al. Almost 200 patients had regrets about their elective treatment and, after 5 years of follow-up, had rupture rates of 9.5%, 10.2%, and 32.5% for aneurysms of 5.5-5.9 cm, 6-6.9 cm, and ≥7 cm, respectively.

We could assume that perioperative COVID-19-related mortality and community risk are equivalent.

This model calculates the “optimal strategy” (repair or deferral) at different timepoints (3, 6, 9, and 12 months) based on baseline characteristics, risk of rupture, surgical risk, and COVID-19-related mortality risk.

The COVID-19 infection risk was stratified by community virus prevalence and nosocomial transmission (estimated as at least twice the community transmission risk).

Results suggest any aneurysm could be deferred for 3 months.


Read also: La durabilidad del TAVI pasa a un segundo plano con los resultados del TRANSIT.


Surgical repair can be deferred up to 6 months only in young patients (<65 years old) with aneurysms >7cm when the risk of COVID-19 transmission is low.

Endovascular repair (non-open) can be deferred 3 months—or even 6 months—in most scenarios, based on the risk of COVID-19 transmission.

These recommendations support deferral for most patients, but also warn that not everyone will conform to this, and decisions must be made on a case-by-case basis.

PIIS1078588421004524free

Original Title: COVID-19 and abdominal aortic aneurysm intervention: when to defer and when to operate.

Reference: Brenig L. Gwilym et al. European Journal of Vascular & Endovascular Surgery 2021. Journal Pre-proof. https://doi.org/10.1016/j.ejvs.2021.05.034.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...